Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients

Chiara Massa; Thomas Karn; Karsten Weber; Andreas Schneeweiss; Claus Hanusch; Jens Uwe Blohmer; Dirk-Michael Zahm; Christian Jackisch; Marion van Mackelenbergh; Jörg Thomalla; Frederik Marmé; Jens Huober; Volkmar Müller; Christian Schem; Anja Müller; Elmar Stickeler; Katharina Biehl; Peter A. Fasching; Michael Untch; Sibylle Loibl; Carsten Denkert; Barbara Seliger

doi:10.1002/ctm2.1617

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (4) : e1617 DOI: 10.1002/ctm2.1617

LETTER TO THE JOURNAL

Baseline CD4⁺ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients

Author information +

¹. Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany

². Institute for Translational Immunology, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany

³. Department of Obstetrics and Gynecology, Goethe University, Frankfurt, Germany

⁴. German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany

⁵. Nationales Centrum für Tumorerkrankungen, Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Germany

⁶. Rotkreuzklinikum München, München, Germany

⁷. Gynäkologie mit Brustzentrum der Charite CCM, Charité-Universitätsmedizin Berlin, Berlin, Germany

⁸. SRH Wald-Klinikum Gera, Gera, Germany

⁹. Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Offenbach, Germany

¹⁰. Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Kiel, Germany

¹¹. Praxis für Hämatologie und Onkologie, Koblenz, Germany

¹². Universitätsfrauenklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Heidelberg, Germany

¹³. Breast Cancer, Cantonal Hospital St.Gallen, St. Gallen, Switzerland

¹⁴. Department of Obstetrics and Gynecology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

¹⁵. Mammazentrum am Krankenhaus Jerusalem, Hamburg, Germany

¹⁶. Klinik für Gynäkologie und Geburtsmedizin, Uniklinik RWTH Aachen, Aachen, Germany

¹⁷. Department of Obstetrics and Gynecology, Universitätsklinikum Erlangen, Erlangen, Germany

¹⁸. Department of Obstetrics and Gynecology, HELIOS Klinikum Berlin Buch, Berlin, Germany

¹⁹. Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany

barbara.seliger@uk-halle.de

Show less

History +

PDF

Cite this article

Download citation ▾

Chiara Massa, Thomas Karn, Karsten Weber, Andreas Schneeweiss, Claus Hanusch, Jens Uwe Blohmer, Dirk-Michael Zahm, Christian Jackisch, Marion van Mackelenbergh, Jörg Thomalla, Frederik Marmé, Jens Huober, Volkmar Müller, Christian Schem, Anja Müller, Elmar Stickeler, Katharina Biehl, Peter A. Fasching, Michael Untch, Sibylle Loibl, Carsten Denkert, Barbara Seliger. Baseline CD4⁺ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients. Clinical and Translational Medicine, 2024, 14(4): e1617 DOI:10.1002/ctm2.1617

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Isaacs J, Anders C, McArthur H, Force J. Biomarkers of immune checkpoint blockade response in triple-negative breast cancer. Curr Treat Options Oncol. 2021;22(5):38.

[2]	Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279-1288.

[3]	Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052-1062.

[4]	Massa C, Karn T, Denkert C, et al. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer. 2020;8(2).

[5]	Zhou B, Gao Y, Zhang P, Chu Q. Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. Front Immunol. 2021;12:693609.

[6]	Kumar D, Mishra A, Lisok A, et al. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proc Natl Acad Sci U S A. 2021;118(37).

[7]	Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, et al. Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer. Clin Cancer Res. 2021.

[8]	Saura-Esteller J, de Jong M, King LA, et al. Gamma delta T-cell based cancer immunotherapy: past-present-future. Front Immunol. 2022;13:915837.

[9]	Holmen Olofsson G, Pedersen SR, Aehnlich P, Svane IM, Idorn M. The capacity of CD4(+) Vgamma9Vdelta2 T cells to kill cancer cells correlates with co-expression of CD56. Cytotherapy. 2021;23(7):582-589.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.